Breaking News, Financial News

Financial Report: Novartis 2Q

Sales in the quarter and YTD were up 8% in local currencies (lc), but were impaired by fluctuations in exchange rates.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 2Q 2Q Revenues: $10.5 billion (-2%) 2Q Earnings: $2.0 billion (-10%) YTD Revenues: $20.3 billion (-2%) YTD Earnings: $4.0 billion (-12%) Comments: Sales in the quarter and YTD were up 8% in local currencies (lc), but were impaired by fluctuations in exchange rates. YTD Pharmaceutical sales were up 3% to $13.5 billion (+11% lc). New products, Lucentis, Exforge, Exjade, Exelon Patch, Reclast/Aclasta and Tekturna/Rasilez, contributed $2.0 billion in sales YTD. This represent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters